drugset / Trial / NCT00811564

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

NCT00811564

Phase 4 Completed 148 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects

Timeline

Start
2008-12
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 0.2 % Other
Comparator Latanoprost Small molecule 0.005 % Other
Comparator Timolol Other / unclassified 0.5 % Other